HighVista Strategies LLC Grows Stake in GH Research PLC $GHRS

HighVista Strategies LLC increased its holdings in GH Research PLC (NASDAQ:GHRS) by 363.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 241,894 shares of the company’s stock after buying an additional 189,647 shares during the period. HighVista Strategies LLC owned 0.46% of GH Research worth $3,459,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Citadel Advisors LLC purchased a new position in shares of GH Research during the 3rd quarter valued at $1,350,000. Boothbay Fund Management LLC increased its position in shares of GH Research by 504.0% in the third quarter. Boothbay Fund Management LLC now owns 83,550 shares of the company’s stock worth $1,195,000 after purchasing an additional 69,717 shares during the last quarter. Man Group plc purchased a new stake in GH Research in the third quarter valued at approximately $315,000. Squarepoint Ops LLC bought a new stake in GH Research during the third quarter valued at approximately $516,000. Finally, Lynx1 Capital Management LP increased its holdings in shares of GH Research by 27.5% in the 3rd quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock worth $122,997,000 after buying an additional 1,854,238 shares during the last quarter. 56.90% of the stock is owned by institutional investors.

GH Research Stock Performance

Shares of GHRS stock opened at $14.95 on Monday. The business’s 50 day moving average price is $15.72 and its 200-day moving average price is $14.34. GH Research PLC has a fifty-two week low of $7.98 and a fifty-two week high of $19.51. The firm has a market cap of $927.35 million, a P/E ratio of -18.69 and a beta of 1.00.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.06. As a group, equities analysts predict that GH Research PLC will post -0.8 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on GHRS shares. Citizens Jmp upped their target price on shares of GH Research from $39.00 to $42.00 and gave the stock a “market outperform” rating in a research report on Friday, March 6th. Guggenheim set a $34.00 price objective on shares of GH Research and gave the stock a “buy” rating in a report on Tuesday, March 10th. Canaccord Genuity Group increased their target price on shares of GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Royal Bank Of Canada raised their price objective on GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Finally, HC Wainwright increased their target price on GH Research from $35.00 to $70.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $40.13.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.